These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 29786857)

  • 1. Effect of OATP1B1/1B3 Inhibitor GDC-0810 on the Pharmacokinetics of Pravastatin and Coproporphyrin I/III in Healthy Female Subjects.
    Liu L; Cheeti S; Yoshida K; Choo E; Chen E; Chen B; Gates M; Singel S; Morley R; Ware J; Sahasranaman S
    J Clin Pharmacol; 2018 Nov; 58(11):1427-1435. PubMed ID: 29786857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling - a case example.
    Chen Y; Zhu R; Ma F; Mao J; Chen EC; Choo EF; Sahasranaman S; Liu L
    Biopharm Drug Dispos; 2018 Nov; 39(9):420-430. PubMed ID: 30335192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GDC-0810 Pharmacokinetics and Transporter-Mediated Drug Interaction Evaluation with an Endogenous Biomarker in the First-in-Human, Dose Escalation Study.
    Cheung KWK; Yoshida K; Cheeti S; Chen B; Morley R; Chan IT; Sahasranaman S; Liu L
    Drug Metab Dispos; 2019 Sep; 47(9):966-973. PubMed ID: 31266752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coproporphyrin I Can Serve as an Endogenous Biomarker for OATP1B1 Inhibition: Assessment Using a Glecaprevir/Pibrentasvir Clinical Study.
    Kalluri HV; Kikuchi R; Coppola S; Schmidt J; Mohamed MF; Bow DAJ; Salem AH
    Clin Transl Sci; 2021 Jan; 14(1):373-381. PubMed ID: 33048456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Organic Anion Transporter Polypeptide 1B1 Polymorphism Modulates the Extent of Drug-Drug Interaction and Associated Biomarker Levels in Healthy Volunteers.
    Yee SW; Giacomini MM; Shen H; Humphreys WG; Horng H; Brian W; Lai Y; Kroetz DL; Giacomini KM
    Clin Transl Sci; 2019 Jul; 12(4):388-399. PubMed ID: 30982223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Further Studies to Support the Use of Coproporphyrin I and III as Novel Clinical Biomarkers for Evaluating the Potential for Organic Anion Transporting Polypeptide 1B1 and OATP1B3 Inhibition.
    Shen H; Christopher L; Lai Y; Gong J; Kandoussi H; Garonzik S; Perera V; Garimella T; Humphreys WG
    Drug Metab Dispos; 2018 Aug; 46(8):1075-1082. PubMed ID: 29777022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Organic anion transporting polypeptide (OATP)-mediated transport of coproporphyrins I and III.
    Bednarczyk D; Boiselle C
    Xenobiotica; 2016; 46(5):457-66. PubMed ID: 26383540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PBPK Modeling of Coproporphyrin I as an Endogenous Biomarker for Drug Interactions Involving Inhibition of Hepatic OATP1B1 and OATP1B3.
    Yoshikado T; Toshimoto K; Maeda K; Kusuhara H; Kimoto E; Rodrigues AD; Chiba K; Sugiyama Y
    CPT Pharmacometrics Syst Pharmacol; 2018 Nov; 7(11):739-747. PubMed ID: 30175555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of Weak Organic Anion-Transporting Polypeptide 1B Inhibition by Probenecid with Plasma-Based Coproporphyrin in Humans.
    Zhang Y; Holenarsipur VK; Kandoussi H; Zeng J; Mariappan TT; Sinz M; Shen H
    Drug Metab Dispos; 2020 Oct; 48(10):841-848. PubMed ID: 32723847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of the organic anion-transporting polypeptide 1B1 by quercetin: an in vitro and in vivo assessment.
    Wu LX; Guo CX; Chen WQ; Yu J; Qu Q; Chen Y; Tan ZR; Wang G; Fan L; Li Q; Zhang W; Zhou HH
    Br J Clin Pharmacol; 2012 May; 73(5):750-7. PubMed ID: 22114872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by Organic Anion Transporting Polypeptide Inhibition.
    Lai Y; Mandlekar S; Shen H; Holenarsipur VK; Langish R; Rajanna P; Murugesan S; Gaud N; Selvam S; Date O; Cheng Y; Shipkova P; Dai J; Humphreys WG; Marathe P
    J Pharmacol Exp Ther; 2016 Sep; 358(3):397-404. PubMed ID: 27317801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rifampin- and Silymarin-Mediated Pharmacokinetic Interactions of Exogenous and Endogenous Substrates in a Transgenic OATP1B Mouse Model.
    Bechtold BJ; Lynch KD; Oyanna VO; Call MR; Graf TN; Oberlies NH; Clarke JD
    Mol Pharm; 2024 May; 21(5):2284-2297. PubMed ID: 38529622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition.
    Gu X; Wang L; Gan J; Fancher RM; Tian Y; Hong Y; Lai Y; Sinz M; Shen H
    Drug Metab Dispos; 2020 Aug; 48(8):724-734. PubMed ID: 32482623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Cyclosporin A and Impact of Dose Staggering on OATP1B1/1B3 Endogenous Substrates and Drug Probes for Assessing Clinical Drug Interactions.
    Mochizuki T; Zamek-Gliszczynski MJ; Yoshida K; Mao J; Taskar K; Hirabayashi H; Chu X; Lai Y; Takashima T; Rockich K; Yamaura Y; Fujiwara K; Mizuno T; Maeda K; Furihata K; Sugiyama Y; Kusuhara H
    Clin Pharmacol Ther; 2022 Jun; 111(6):1315-1323. PubMed ID: 35292967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarker-Informed Model-Based Risk Assessment of Organic Anion Transporting Polypeptide 1B Mediated Drug-Drug Interactions.
    Kimoto E; Costales C; West MA; Bi YA; Vourvahis M; David Rodrigues A; Varma MVS
    Clin Pharmacol Ther; 2022 Feb; 111(2):404-415. PubMed ID: 34605015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Investigation of Coproporphyrins as Sensitive Biomarkers to Predict Mild to Strong OATP1B-Mediated Drug-Drug Interactions.
    Kunze A; Ediage EN; Dillen L; Monshouwer M; Snoeys J
    Clin Pharmacokinet; 2018 Dec; 57(12):1559-1570. PubMed ID: 29663259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of organic anion transporting polypeptide 1B1 and 1B3 humanized mice as a translational model to study the pharmacokinetics of statins.
    Salphati L; Chu X; Chen L; Prasad B; Dallas S; Evers R; Mamaril-Fishman D; Geier EG; Kehler J; Kunta J; Mezler M; Laplanche L; Pang J; Rode A; Soars MG; Unadkat JD; van Waterschoot RA; Yabut J; Schinkel AH; Scheer N
    Drug Metab Dispos; 2014 Aug; 42(8):1301-13. PubMed ID: 24855184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Ipatasertib Interactions with Itraconazole and Coproporphyrin I and III in a Single Drug Interaction Study in Healthy Subjects.
    Sane RS; Cheung KWK; Cho E; Liederer BM; Hanover J; Malhi V; Plise E; Wong S; Musib L
    J Pharmacol Exp Ther; 2021 Aug; 378(2):87-95. PubMed ID: 34049965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors of Organic Anion-Transporting Polypeptides 1B1 and 1B3: Clinical Relevance and Regulatory Perspective.
    McFeely SJ; Ritchie TK; Yu J; Nordmark A; Berglund EG; Levy RH; Ragueneau-Majlessi I
    J Clin Pharmacol; 2020 Aug; 60(8):1087-1098. PubMed ID: 32196692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril.
    Maeda K; Ieiri I; Yasuda K; Fujino A; Fujiwara H; Otsubo K; Hirano M; Watanabe T; Kitamura Y; Kusuhara H; Sugiyama Y
    Clin Pharmacol Ther; 2006 May; 79(5):427-39. PubMed ID: 16678545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.